Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (CSE: MDMA ) 0.1050 -0.0050 (-4.55%) Streaming Delayed Price Updated: 12:43 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 216,891 Open 0.1100 Bid (Size) 0.1050 (5,000) Ask (Size) 0.1100 (37,000) Prev. Close 0.1100 Today's Range 0.1050 - 0.1100 52wk Range 0.0850 - 0.3500 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale May 29, 2024 Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products. Read now! Via Benzinga Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia April 05, 2024 Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities From PharmAla Biotech Via GlobeNewswire Performance YTD -30.00% -30.00% 1 Month -8.70% -8.70% 3 Month -46.15% -46.15% 6 Month -38.24% -38.24% 1 Year -68.18% -68.18% More News Read More Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office March 27, 2024 From PharmAla Biotech Via GlobeNewswire Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office March 20, 2024 From PharmAla Biotech Via GlobeNewswire Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme March 18, 2024 From PharmAla Biotech Via GlobeNewswire PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing January 24, 2024 From PharmAla Biotech Via GlobeNewswire PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance January 08, 2024 From PharmAla Biotech Via GlobeNewswire PharmAla Begins Trading on OTCQB September 06, 2023 From PharmAla Biotech Via GlobeNewswire PharmAla Files Patent for Novel MDXX Molecule PharmAla-1 July 31, 2023 From PharmAla Biotech Via GlobeNewswire Life Science Investor Forum: Presentations Now Available for Online Viewing June 23, 2023 From Virtual Investor Conferences Via GlobeNewswire Life Science Investor Forum Agenda Announced for June 22nd June 20, 2023 From Virtual Investor Conferences Via GlobeNewswire USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States June 09, 2023 From PharmAla Biotech Via GlobeNewswire PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health May 01, 2023 From PharmAla Biotech Via GlobeNewswire Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development February 06, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change February 03, 2023 From PharmAla Biotech Via GlobeNewswire The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News January 27, 2023 Via ACCESSWIRE KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing December 16, 2022 From Virtual Investor Conferences Via GlobeNewswire PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference December 13, 2022 From Virtual Investor Conferences Via GlobeNewswire KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th December 13, 2022 From Virtual Investor Conferences Via GlobeNewswire Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement November 16, 2022 From PharmAla Biotech Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
